NovaGo Therapeutics AG: Phase 1 study in Acute Spinal Cord Injury (SCI), Spinal Cord Diseases (120 participants)
NovaGo Therapeutics AG: Phase 1 study in Acute Spinal Cord Injury (SCI), Spinal Cord Diseases (120 participants). Its enrollment of 120 is above the median of 80 (65th percentile). Dated 42 days ago, it serves as a historical benchmark. Score 50/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 120 · 65th percentile of 8,879 ClinicalTrialStartPulse records · 1.5x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | NovaGo Therapeutics AG |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | NG004 in Incomplete Spinal Cord Injury Patients |
| NCT ID | NCT07840196 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Acute Spinal Cord Injury (SCI); Spinal Cord Diseases; Spinal Cord Injuries; Trauma Nervous System |
| Intervention types | drug, other |
| Target enrollment | 120 |
| Site countries | Germany, Switzerland |
| Posted | 2026-09-24 |
| Planned start | 2026-08-05 |
| Event | Newly registered study |
| Event date | 2026-09-24 |
| enrollment percentile | 65th of 8,879 (median 80, 1.5x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch NovaGo Therapeutics AG
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock NovaGo Therapeutics AG + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-09-24
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: NovaGo Therapeutics AG and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- NovaGo Therapeutics AG's enrollment: 65th percentile of 8,879 records
- Timing: Low: older than 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
50 / 100 Score
- Industry sponsor (buys outsourced services).
- 120 participants planned.
What is the ClinicalTrialStartPulse record for NovaGo Therapeutics AG?
NovaGo Therapeutics AG registered a Phase 1 study (NCT07840196) in Acute Spinal Cord Injury (SCI) targeting 120 participants, posted 2026-09-24.
How does NovaGo Therapeutics AG compare to other ClinicalTrialStartPulse records?
Its enrollment of 120 sits in the upper half (65th percentile) of 8,879 records; the median is 80. It is 42 days old, still within a typical 45-day follow-up window.
NovaGo Therapeutics AG vs. top 2 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| NovaGo Therapeutics AG | NONUS | 120 | 65th | 2026-09-24 |
| Jiangsu Simcere Pharmaceutical Co., Ltd. | NONUS | 270 | 81st | 2026-11-03 |
| Mabsoft Therapeutics (Shanghai) Co., Ltd. | NONUS | 420 | 88th | 2026-10-28 |
Related records
- Hoffmann-La Roche
- MacroGenics
- Mabsoft Therapeutics (Shanghai) Co., Ltd.
- Sutro Biopharma, Inc.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Genentech, Inc.
ClinicalTrialStartPulse: Phase 1 ClinicalTrialStartPulse: Outside the US only
How to monitor NovaGo Therapeutics AG and peer phase 1 records
Get new ClinicalTrialStartPulse records like NovaGo Therapeutics AG by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.